Neomorph
neomorph.com
Professional Services
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$209M
2 rounds on record
Latest round
$100M
Series B · Apr 2026 · 6 mo ago
The money's age
Fresh money
6 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 13
Board appointment Neomorph Appoints Biopharma Leader Robert J. Hugin as Chairman of the Board · neomorph.com
Apr 13
Raised a round Series B $100M
Jan 23, 2025
Partnership AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology · neomorph.com
Jan 14, 2025
New executive Neomorph Announces Appointment of Dr. Klaus Wagner, M.D., Ph.D. as Chief Medical Officer · prnewswire.com
Oct 28, 2024
Partnership Biogen And Neomorph Collaborate To Develop Molecular Glue Degraders For Alzheimer's And More · nasdaq.com
Aug 20, 2024
Board appointment Neomorph Announces Appointment of Dr. Peter Lebowitz, M.D., Ph.D. to its Board of Directors · PRNewswire
Sep 7, 2022
New executive Neomorph, Inc. Announces Appointment of Chief Financial Officer · neomorph.com
Dec 22, 2020
Raised a round Series A $109M · businesswire
2020
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Apr 2026 | $100M | — | neomorph.com |
| Series A | Dec 2020 | $109M | — | businesswire |
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Enodia Therapeutics pioneers targeted protein degradation at the Sec61 translocon, developing small-molecule therapies for inflammatory and…
KiloGen Therapeutics specializes in proximity pharmacology, molecular glues, targeted protein degradation (TPD), biotechnology, drug…
Pioneering Protein Degradation for Targeted Therapies. Laigo Bio is at the forefront of a revolutionary era in biotechnology -one that…
Together we are transforming the future of Targeted Protein Degradation Our people are at the heart of our success Our commitment to…
Discover the future of molecular glues with Coltac Therapeutics. Using a cutting-edge bacteria-based positive selection screening system…
Pioneering the development of cell-specific, targeted protein degraders with the precision of antibody targeting.
News
Neomorph Appoints Biopharma Leader Robert J. Hugin as Chairman of the Board
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc., a biotechnology company advancing a new class of molecular glue degraders to target historically undruggable proteins, today announced the appointment of Bob Hugin, former Chairman and Chief Exec
Read more
Report
Neomorph Appoints Biopharma Leader Robert J. Hugin as Chairman of the Board
SAN DIEGO, CA, May 13, 2026 (GLOBE NEWSWIRE) - Neomorph, Inc., a biotechnology company advancing a new class of molecular glue degraders to target historically undruggable proteins, today announced the appointment of Bob Hugin, former Chairman and Chief E
Read more
Report
Neomorph to Highlight Progress in Targeted Protein Degradation Science at the American Association for Cancer Research Annual Meeting
Presentation in the New Drugs on the Horizon session to feature the development of NEO-811, a novel ARNT (HIF-1β)-targeted therapy in clear cell renal cell carcinoma (ccRCC) Three additional presentations to highlight NEO-811 preclinical characterization
Read more
Report
Neomorph Announces Closing of $100 Million Series B Financing
Financing will support the ongoing Phase 1/2 trial of NEO-811 for the treatment of locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC) and the continued advancement of the company's broader novel molecular glue degrader p
Read more
Report
Neomorph Announces Closing of $100 Million Series B Financing
Financing will support the ongoing Phase 1/2 trial of NEO-811 for the treatment of locally advanced or metastatic non-resectable clear cell renal cell carci ...
Read more
Report
Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Initiation of trial marks first-in-human milestone for Neomorph's novel molecular glue degrader platform
Read more
Report
Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Initiation of trial marks first-in-human milestone for Neomorph's novel molecular glue degrader platform SAN DIEGO, CA, Feb. 3, 2026 (GLOBE NEWSWIRE) - Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undru
Read more
Report
AbbVie Inks a Deal With Neomorph for Molecular Glue Degraders
Per the terms of the deal, AbbVie will use Neomorph
Read more
Report
AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible to receive future option fees and milestones of up to $1
Read more
Report
Neomorph Announces Appointment of Dr. Klaus Wagner, M.D., Ph.D. as Chief Medical Officer
SAN DIEGO, Jan. 14, 2025 /PRNewswire/ - Neomorph, Inc., today announced the appointment of Dr. Klaus Wagner as Chief Medical Officer. Dr. Wagner is a seasoned biotech executive with extensive experience in guiding the development of oncology therapeutics
Read more
Report
Show more news